{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T21:39:38Z","timestamp":1772228378341,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,3,19]],"date-time":"2015-03-19T00:00:00Z","timestamp":1426723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s40264-015-0282-z","type":"journal-article","created":{"date-parts":[[2015,3,18]],"date-time":"2015-03-18T09:29:32Z","timestamp":1426670972000},"page":"511-515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Relationship Between Structural Alerts in NSAIDs and Idiosyncratic Hepatotoxicity: An Analysis of Spontaneous Report Data from the WHO Database"],"prefix":"10.1007","volume":"38","author":[{"given":"Naomi","family":"Jessurun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"van Puijenbroek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,19]]},"reference":[{"issue":"3","key":"282_CR1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/1389200054021799","volume":"6","author":"AS Kalgutkar","year":"2005","unstructured":"Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, et al. A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab. 2005;6(3):161\u2013225.","journal-title":"Curr Drug Metab"},{"issue":"2","key":"282_CR2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1081\/DMR-120034148","volume":"36","author":"B Gunawan","year":"2004","unstructured":"Gunawan B, Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev. 2004;36(2):301\u201312.","journal-title":"Drug Metab Rev."},{"issue":"22","key":"282_CR3","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1359-6446(03)02888-5","volume":"8","author":"DP Williams","year":"2003","unstructured":"Williams DP, Park BK. Idiosyncratic toxicity: the role of toxicophores and bioactivation. Drug Discov Today. 2003;8(22):1044\u201350.","journal-title":"Drug Discov Today"},{"key":"282_CR4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-3-642-00663-0_7","volume":"196","author":"A Srivastava","year":"2010","unstructured":"Srivastava A, Maggs JL, Antoine DJ, Williams DP, Smith DA, Park BK. Role of reactive metabolites in drug-induced hepatotoxicity. Handb Exp Pharmacol. 2010;196:165\u201394.","journal-title":"Handb Exp Pharmacol."},{"issue":"18","key":"282_CR5","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1001\/jama.281.18.1728","volume":"281","author":"MA Friedman","year":"1999","unstructured":"Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA. 1999;281(18):1728\u201334.","journal-title":"JAMA"},{"issue":"3","key":"282_CR6","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/hep.1840220320","volume":"22","author":"AT Banks","year":"1995","unstructured":"Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology. 1995;22(3):820\u20137.","journal-title":"Hepatology"},{"key":"282_CR7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev.pa.28.040188.002055","volume":"28","author":"LR Pohl","year":"1988","unstructured":"Pohl LR, Satoh H, Christ DD, Kenna JG. The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol Toxicol. 1988;28:367\u201387.","journal-title":"Annu Rev Pharmacol Toxicol."},{"issue":"7","key":"282_CR8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/bdd.720","volume":"31","author":"SL Regan","year":"2010","unstructured":"Regan SL, Maggs JL, Hammond TG, Lambert C, Williams DP, Park BK. Acyl glucuronides: the good, the bad and the ugly. Biopharm Drug Dispos. 2010;31(7):367\u201395.","journal-title":"Biopharm Drug Dispos."},{"issue":"4","key":"282_CR9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1517\/17425255.4.4.425","volume":"4","author":"C Skonberg","year":"2008","unstructured":"Skonberg C, Olsen J, Madsen KG, Hansen SH, Grillo MP. Metabolic activation of carboxylic acids. Expert Opin Drug Metab Toxicol. 2008;4(4):425\u201338.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"5","key":"282_CR10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1124\/dmd.32.5.566","volume":"32","author":"JB Mangold","year":"2004","unstructured":"Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos. 2004;32(5):566\u201371.","journal-title":"Drug Metab Dispos."},{"issue":"2","key":"282_CR11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/dmd.107.019018","volume":"36","author":"Y Li","year":"2008","unstructured":"Li Y, Slatter JG, Zhang Z, Li Y, Doss GA, Braun MP, Stearns RA, Dean DC, Baillie TA, Tang W. In vitro metabolic activation of lumiracoxib in rat and human liver preparations. Drug Metab Dispos. 2008;36(2):469\u201373.","journal-title":"Drug Metab Dispos."},{"issue":"1","key":"282_CR12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1021\/tx8002356","volume":"22","author":"P Kang","year":"2009","unstructured":"Kang P, Dalvie D, Smith E, Renner M. Bioactivation of lumiracoxib by peroxidases and human liver microsomes: identification of multiple quinone imine intermediates and GSH adducts. Chem Res Toxicol. 2009;22(1):106\u201317.","journal-title":"Chem Res Toxicol."},{"issue":"12","key":"282_CR13","first-page":"1608","volume":"29","author":"GK Poon","year":"2001","unstructured":"Poon GK, Chen Q, Teffera Y, Ngui JS, Griffin PR, Braun MP, et al. Bioactivation of diclofenac via benzoquinone imine intermediates-identification of urinary mercapturic acid derivatives in rats and humans. Drug Metab Dispos. 2001;29(12):1608\u201313.","journal-title":"Drug Metab Dispos."},{"issue":"9","key":"282_CR14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1021\/tx200168d","volume":"24","author":"AF Stepan","year":"2011","unstructured":"Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, et al. Structural alert\/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol. 2011;24(9):1345\u2013410.","journal-title":"Chem Res Toxicol."},{"key":"282_CR15","unstructured":"The database of the World Health Organization Collaborating Centre for International Drug Monitoring (VigiBase) (version date: 3 Feb 2015). https:\/\/tools.who-umc.org\/webroot\/ . Accessed 1 May 2014."},{"issue":"4","key":"282_CR16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/pds.848","volume":"12","author":"N Moore","year":"2003","unstructured":"Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, Begaud B. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf. 2003;12(4):271\u201381.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7151","key":"282_CR17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/bmj.317.7151.119","volume":"317","author":"RM Martin","year":"1998","unstructured":"Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of suspected adverse drug reactions to newly marketed (\u201cblack triangle\u201d) drugs in general practice: observational study. BMJ. 1998;317(7151):119\u201320.","journal-title":"BMJ"},{"issue":"6","key":"282_CR18","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s002280050498","volume":"54","author":"A Alvarez-Requejo","year":"1998","unstructured":"Alvarez-Requejo A, Carvajal A, Begaud B, Moride Y, Vega T, Arias LH. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol. 1998;54(6):483\u20138.","journal-title":"Eur J Clin Pharmacol."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0282-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-015-0282-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0282-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:41:35Z","timestamp":1559504495000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-015-0282-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,19]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["282"],"URL":"https:\/\/doi.org\/10.1007\/s40264-015-0282-z","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,19]]}}}